Personalized treatment for CHCHD10 ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a personalized medicine approach for people with a specific genetic form of ALS caused by changes in the CHCHD10 gene. A custom-designed antisense oligonucleotide (a type of genetic therapy) is used to target the underlying cause of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis, specifically a change in the CHCHD10 gene linked to ALS.
- You need to be able to travel to the study site and attend follow-up visits.
- You or your legal representative must give informed consent to participate.
- You cannot be taking any other experimental medications within a certain time before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is designed for one specific patient with a rare genetic form of ALS caused by a mutation in the CHCHD10 gene. It tests an experimental therapy made just for that person's genetic mutation, aiming to slow or stop the disease.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.
This trial tests RAPA-501, a treatment made using your own immune cells, to slow progression of ALS. It may help by changing how your immune system responds in ALS.
This trial offers a custom-made treatment for people with ALS caused by a TARDBP gene mutation. It uses a personalized medicine approach to target the specific genetic cause of the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.